Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM Trial (Tasigna Efficacy in Advanced Melanoma)
2009-015514-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nilotinib in melanoma (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Mar 2010; status: completed.
02
Drugs
nilotinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-015514-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015514-21.